(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 2.47% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Bioventus's revenue in 2025 is $567,699,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $46,529,022,471, with the lowest BVS revenue forecast at $46,529,022,471, and the highest BVS revenue forecast at $46,529,022,471. On average, 1 Wall Street analysts forecast BVS's revenue for 2026 to be $48,968,709,577, with the lowest BVS revenue forecast at $48,968,709,577, and the highest BVS revenue forecast at $48,968,709,577.
In 2027, BVS is forecast to generate $51,405,932,353 in revenue, with the lowest revenue forecast at $51,405,932,353 and the highest revenue forecast at $51,405,932,353.